Table 1.
Patient characteristics: squamous cell carcinoma (SSC), superior-inferior direction (SI), anterior-posterior direction (AP), cisplatin (DDP)
| Patient | Age (years) | Clinical T N stage | Stage | Histology | Motion amplitude in SI direction (mm) | GTV volume in planning CT (cm3) | Single dose (Gy) | Total dose (Gy) | Simultaneous chemotherapy |
|---|---|---|---|---|---|---|---|---|---|
| Pat #1 | 48,8 | T4 N2 | IIIB | Adeno Ca | < 5 | 42.2 | 2 | 66 | DDP + Navelbine |
| Pat #2 | 52,6 | T3 N3 | IIIB | Adeno Ca | 12 | 60 | 2 | 66 | DDP + Navelbine |
| Pat #3 | 71,5 | T4 N2 | IIIB | SSC | < 5 (5 mm AP) | 62.1 | 2 | 70 | DDP + Navelbine |
| Pat #4 | 56,8 | T3 N1 | IIIA | SSC | 14 | 109.1 | 2 | 62 | DDP + Navelbine |
| Pat #5 | 49,0 | T2 N2 | IIIA | Adeno Ca | 11 | 147.2 | 2 | 66 | DDP + Navelbine |
| Pat #6 | 34,9 | T4 N2 | IIIB | Adeno Ca | < 5 | 160.1 | 2 | 70 | DDP + Navelbine |
| Pat #7 | 74,2 | T4 N2 | IIIB | Adeno Ca | < 5 | 169.3 | 2 | 66 | DDP + Navelbine |
| Pat #8 | 75,2 | T4 N1 | IIIA | Adeno Ca | < 5 | 202.9 | 2 | 66 | DDP + Navelbine |
| Pat #9 | 61,7 | T3 N2 | IIIA | Undifferentiated NSCLC | 10 | 2 | 216.1 | 66 | DDP + Navelbine |
| Pat #10 | 82,1 | T4 N2 | IIIB | Adeno Ca | < 5 | 225.2 | 2 | 66 | none |
| Pat #11 | 57,6 | T4 N3 | IIIB | Neuroendocrine Ca | < 5 | 302.8 | 2 | 66 | DDP + Navelbine |
| Pat #12 | 63,5 | T4 N3 | IIIB | Undifferentiated NSCLC | < 5 | 352.0 | 2 | 66 | DDP + Navelbine |
| Pat #13 | 68,8 | T2 N2 | IIIA | SSC | < 5 | 382.5 | 2 | 70 | DDP + Navelbine |